Drugs / Burlulipase
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01710644 | May 2013 → Jul 2014 | cystic fibrosis, exocrine pancreatic insufficiency, lung disorder | Nordmark Arzneimittel GmbH & Co. KG | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Burlulipase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01710644 ↗ |
| Route | Oral | “Burlulipase oral solution will be taken with meals and snacks for 5 to 7 days” NCT01710644 ↗ |